參考文獻 |
1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-55.
2. Fabbri LM, Hurd SS. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J. 2003;22:1-2.
3. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675-679.
4. Lee CH, Lee MC, Shu CC, Lim CS, Wang JY, Lee LN, Chao KM. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis 13(1): 194.
5. David Price, Barbara Yawn, Guy Brusselle, Andrea Rossi. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013; 22(1): 92-100
6. Congdon N, Vingerling J R, Klein B E. et al Eye Diseases Prevalence Research Group. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 2004. 122487–494.494
7. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8–14.
8. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280: 539–543.
9. P. Ernst, M. Baltzan, J. Descheˆnes and S. Suissa. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006; 27: 1168–1174 DOI: 10.1183/09031936.06.00043005.
10. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004 May 22;363(9422):1711–20.
11. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996 May;80(5):389–93
12. Anne V. Gonzalez , Gisele Li , Samy Suissa , Pierre Ernst. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulmonary Pharmacology & Therapeutics 23 (2010) 65–70.
13. Ryskulova A, Turczyn K, Makuc DM, Cotch MF, Klein RJ, Janiszewski R. Self-reported age-related eye diseases and visual impairment in the United States: results of the 2002 national health interview survey. Am J Public Health. 2008;98:454–461.
14. Etminan M, Brophy JM, Maberley D. Use of statins and angiotensin converting enzyme inhibitors (ACE-Is) and the risk of age-related macular degeneration: nested case-control study. Curr Drug Saf. 2008;3:24–26.
15. Nowak J.Z. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol. Rep. 2006;58:353-363.
16. Elin Drivenes, Anders Østrem and Hasse Melbye. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Family Practice 2014, 15:42.
17. Caramori G, Chung KF, Adcock IM. Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.Int J Chron Obstruct Pulmon Dis. 2014 Feb 24;9:249-56.
18. Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology 2001; 12: 229–234.
19. David P Miller, Stephanie E Watkins, Tim Sampson, Kourtney J Davis. Long-term use of fluticasone propionate salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. International Journal of COPD 2011:6 467–476.
20. Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, et al. (2009) Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology 14: 983–990.
21. Gartlehner G, Hansen RA, Carson SS, Lohr KN. The efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4:253–262.
22. Smeeth L, Boulis M, Hubbard R, Fletcher AE. A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthalmol. 2003;87:1247–1251.
23. Uboweja A, Malhotra S, Pandhi P. Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis development of cataract: a meta-analysis. Fundam Clin Pharmacol. 2006;20(3):305–309.
24. Vogelmeier, C F. Possible Harms of Theophylline in Chronic Obstructive Pulmonary Disease. Dtsch Arztebl Int 2014; 111(17): 291-2.
25. WU Jun-ping, WU Qi, SUN Xin and SUN Hong-fen. Corticosteroid resistance in chronic obstructive pulmonary disease: new uses of theophylline.Chinese Medical Journal 2013;126 (5)
26. Meng-Ting Wang, Cheng-Liang Tsai, Yu-Wen Lo, Jun-Ting Liou, Wan-Ju Lee, I-Ching Lai. Risk of stroke associated with inhaled ipratropium bromide in chronic obstructive pulmonary disease: A population-based nested case–control study. International Journal of Cardiology 158 (2012) 279–284.
27. Manuela M. Bergmann, Tim Byers, David S. Freedman, and Ali Mokdad . Validity of Self-reported Diagnoses Leading to Hospitalization: A Comparison of Self-reports with Hospital Records in a Prospective Study of American Adults. Am. J. Epidemiol. (1998) 147(10): 969-977.
28. Duanping Liao, Jingping Mo, Yinkang Duan, Ronald Klein, Ingrid U. Scott, Kui A. Huang and Haibo Zhou. Is Age-Related Macular Degeneration Associated with Stroke Among Elderly Americans? The Open Ophthalmology Journal, 2008, 2, 37-42
29. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol.1992;45:613-619.
30. Wang CY, Lin YS, Tzao C, et al. Comparison of Charlson comorbidity index and Kaplan-Feinstein index in patients with stage I lung cancer after surgical resection. Eur J Cardiothorac Surg 2007;32:877–881.
31. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis Management and Prevention of COPD 2014 update.
32. Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G. Prevalence of Comorbidities in Patients with Chronic Obstructive Pulmonary Disease. Respiration. 2010;80(2):112-9.
33. F Abuekteish, J N Kirkpatrick, G Russell. Posterior subcapsular cataract and inhaled corticosteroid therapy.Thorax 1995;50:674-676.
|